Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNOPHYLATE vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SYNOPHYLATE is a bronchodilator that inhibits phosphodiesterase, leading to increased intracellular c AMP. It also acts as an adenosine receptor antagonist and enhances histone deacetylase activity, causing relaxation of bronchial smooth muscle.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of bronchial asthma,Chronic bronchitis,Emphysema,Acute asthmatic exacerbations (off-label)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
400-800 mg orally every 6-8 hours; maximum 3200 mg/day.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal elimination half-life is 3-4 hours in healthy adults, but can be prolonged to 6-8 hours in neonates, cirrhotic patients, or those with heart failure. Clinical context: Requires frequent dosing or extended-release formulations to maintain therapeutic levels.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via CYP1A2 and CYP3A4 isoenzymes.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal excretion of unchanged drug accounts for approximately 10-20% of elimination; hepatic metabolism via CYP450 (primarily CYP1A2, CYP3A4) accounts for the remainder. Biliary/fecal excretion of metabolites is minor (<5%).
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Approximately 40-60% bound, primarily to albumin.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
Vd is approximately 0.3-0.7 L/kg, indicating distribution into total body water. Higher Vd in hyperthyroid states, lower in obesity.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral: 80-100% for immediate-release; 90-100% for extended-release. Rectal: 80-90%.
Oral: 40-50%; Inhalation: 20-30%
GFR 30-50 m L/min: 50% of normal dose; GFR <30 m L/min: 25% of normal dose or extend interval to 12-24 hours.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 50% of normal dose; Child-Pugh C: contraindicated or 25% of normal dose with monitoring.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
10-15 mg/kg/dose orally every 6-8 hours; maximum 60 mg/kg/day.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Start at 300 mg every 8 hours; titrate cautiously due to increased risk of accumulation and adverse effects.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
None.
No FDA black box warning.
Narrow therapeutic index; monitor serum levels. Dosage should be individualized. Avoid excessive caffeine intake.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to xanthine derivatives, active peptic ulcer disease, and seizure disorders.
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) and charcoal-grilled foods, which can reduce theophylline absorption. High-fat meals may increase absorption; take consistently with meals.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
First trimester: Increased risk of neural tube defects and cardiovascular malformations. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal nephrotoxicity. Late third trimester: Risk of premature closure of ductus arteriosus and persistent pulmonary hypertension of the newborn.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Contraindicated during breastfeeding due to high M/P ratio of 3.5, leading to significant infant exposure with potential for adverse effects including renal impairment and gastrointestinal bleeding.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
No dose adjustment required; pharmacokinetics unchanged in pregnancy. However, avoid use after 28 weeks gestation due to fetal renal effects.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
SYNOPHYLATE (theophylline) has a narrow therapeutic index; serum levels should be monitored to maintain 5-15 mcg/m L. Use with caution in patients with heart failure, liver disease, or COPD, as clearance is reduced. Cimetidine, fluoroquinolones, and macrolides increase levels; smoking and carbamazepine decrease levels. Avoid in seizure disorders.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without medical advice, as it affects drug levels.,Inform all healthcare providers you are taking this medication, especially if starting new drugs.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNOPHYLATE vs AEROLATE III, answered by our medical review team.
SYNOPHYLATE is a Bronchodilator that works by SYNOPHYLATE is a bronchodilator that inhibits phosphodiesterase, leading to increased intracellular c AMP. It also acts as an adenosine receptor antagonist and enhances histone deacetylase activity, causing relaxation of bronchial smooth muscle.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNOPHYLATE and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNOPHYLATE is: 400-800 mg orally every 6-8 hours; maximum 3200 mg/day.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNOPHYLATE and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNOPHYLATE is classified as Category C. First trimester: Increased risk of neural tube defects and cardiovascular malformations. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal n. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.